This study tests whether a vaginal insert called ABI-2280 can clear persistent high-risk human papillomavirus (HPV) infection in women aged 25 to 55. Participants receive either the active insert or a placebo to compare safety and effectiveness. The goal is to see if the treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Antiva Biosciences • Aim: Disease control
Last updated May 14, 2026 12:06 UTC